Two PK metrics: Inflation of the Type I Error [Two-Stage / GS Designs]

posted by Helmut Homepage – Vienna, Austria, 2017-11-12 12:57 (2328 d 10:19 ago) – Posting: # 17971
Views: 9,884

Dear all,

related to this thread about dropouts. To run the R-code you need package Power2Stage 0.4.6+.

Let’s assume a CV of 25% for Cmax and 15% for AUC, Potvin ‘Method B’ (αadj 0.0294). We want to play it safe and plan the first stage like a fixed sample design (T/R 0.95, 80% power). Hence, we start with 28 subjects. In the interim the CVs are higher than expected; for Cmax a CV of 30% and for AUC 20%. Say Cmax is not BE (94.12% CI) and power <80%. Hence, we should initiate the second stage. Re-estimated sample size:

library(Power2Stage)
print(sampleN2.TOST(CV=0.30, n1=28), row.names=FALSE) # Cmax
# Design  alpha  CV theta0 theta1 theta2 n1 Sample size Achieved power Target power
#    2x2 0.0294 0.3   0.95    0.8   1.25 28          20      0.8177478          0.8

What does that mean? We would initiate the second stage with 20 subjects for Cmax but possible shouldn’t for AUC:

print(sampleN2.TOST(CV=0.20, n1=28), row.names=FALSE) # AUC
# Design  alpha  CV theta0 theta1 theta2 n1 Sample size Achieved power Target power
#    2x2 0.0294 0.2   0.95    0.8   1.25 28           0      0.8922371          0.8

Since the Type I Error strongly depends on the sample size, the study would be overrun for AUC and an inflated TIE is quite possible. If have no R-code yet to estimate how much… Suggestions are welcome.
I think that in the past everybody (including myself) looked only at the PK metric with the highest variability and ignored the other one. Likely not a good idea.

Which options do we have for the PK metric with the lower variability?
  1. Assess BE with a lower sample size. In the example above ignore the second stage entirely. If the CV would be 25% instead of 20%, assess only the first six subjects of the 20 in the second stage (i.e., in the pooled analysis 28+6=34 instead of 48).
  2. Use the data of all subjects and adjust α more (i.e., a wider CI). How?
  3. Or?
#1 would preserve the TIE but would regulators accept it (not using all available data)? What about #2, when the GL tells us that the α has to be pre-specified in the protocol?

Of course, this issue is not limited to TSDs but applies to GSDs with (blinded/unblinded) sample size re-estimation as well.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,636 registered users;
82 visitors (0 registered, 82 guests [including 7 identified bots]).
Forum time: 23:17 CET (Europe/Vienna)

Nothing shows a lack of mathematical education more
than an overly precise calculation.    Carl Friedrich Gauß

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5